Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Remarkable Spots for Hot Air Swelling All over The Planet- Several injured as man threatens attack on German high-speed train
- 5 High Limit Outer Hard Drives For Information Stockpiling
- Which European palace do you fantasy about visiting? Vote!
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- Are your hormones imbalanced? Doctors explain how to know if you need testing
- Radiated Tortoise Faces Rapid Decline in Madagascar
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Vote In favor of Your #1 sort of film
